Compared with AChR-Ab-positive MG, IVIG is less effective in MuSK-Ab-positive MG, with only 20% to 61% of muscle-specific kinase antibody-positive MG patients in previous studies improved with IVIG [25–27]. The gene discussed is MUSK; the disease is myasthenia gravis.